Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAIN-3 image-guided de-escalation neoadjuvant therapy in HER2-positive breast cancer
NL-OMON59225Phase 2Active, not recruiting
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pertuzumab and trastuzumab in breast cancer, sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Three-year event-free survival. Started Apr 2019; status: active, not recruiting.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON59225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59225.